Cipla expects US business to draw support from upcoming product pipeline

Benchmarks Nifty22,754.050.85FEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.32 % Invest NowFEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.45 % Invest NowEnter search text:

The Economic Times daily newspaper is available online now. Read Today's Paper Cipla expects US business to draw support from upcoming product pipelineET OnlineLast Updated: Oct 27, 2026, 03:09:00 PM ISTSynopsis

Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.

Cipla expects its North American business to remain supported by its upcoming product pipeline, the drugmaker said on Tuesday, even as intensifying competition and tapering sales of generic Revlimid weighed on its US performance in the September quarter.

India’s third-largest drugmaker by revenue reported a 35% year-on-year decline in consolidated net profit to Rs 878 crore for the second quarter of FY27, missing analysts’ estimates of Rs 942 crore, according to data compiled by LSEG. Net profit stood at Rs 1,351 crore in the year-ago quarter.

Also Read: Cipla subsidiary clears USFDA inspection with zero observations

Cipla’s North America revenue fell 19% during the quarter, reflecting continued pressure on sales of generic Revlimid, Bristol Myers Squibb’s blood cancer drug, as competition increased. The company, however, said its US business posted revenue of $172 million during the quarter, continuing its sequential growth trajectory.

“We expect North America performance to remain supported by our upcoming product pipeline,” the company said.

Live Events

The US business remains a key pressure point for Cipla as generic Revlimid sales taper, increasing the importance of its product pipeline and growth in other markets. India, which accounts for a significant share of the company’s revenue alongside North America, continued to provide support, with domestic revenue rising 12% year on year.

Cipla is also looking to newer launches to strengthen growth in India, including Yurpeak, its brand of Eli Lilly’s tirzepatide, which it markets under a partnership with the US drugmaker. The obesity drug is expected to add to the company’s growth opportunities as its US business navigates competitive pressures.

Revenue from operations declined 2.4% year on year to Rs 7,404 crore during the quarter. The company said the reported revenue was affected in part by a reclassification effective April 1, 2026, under which certain marketing and promotional expenses are presented as a reduction from revenue instead of under other expenses. The change had no impact on profit or cash flows.

Also Read: Indian pharma: Unethical practices, marketing rules under lens; new review body set up

India and North America together contribute about two-thirds of Cipla’s revenue, making performance in the two markets central to its overall growth trajectory.

Outside the US, Cipla said its South Africa private-market business continued to outperform the market, growing approximately 1.3 times faster than the market.

“We continue to focus on sustained growth in our core businesses, improving productivity, strengthening our pipeline in order to serve patients with trusted, high-quality medicines,” the company said.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onciplaCipla US businessCipla North America revenueCipla product pipelineCipla India revenueCipla financial results Q2 FY27

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...moreless
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onciplaCipla US businessCipla North America revenueCipla product pipelineCipla India revenueCipla financial results Q2 FY27

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...morelessContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories
& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Login using your ET Prime credentials to enjoy all member benefits

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Big Price Drop! Flat 40% Off

Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail OfferAvail OfferClaim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '

' + h3 + '

' + h4 + '

' + listing + '

'; $('#paidSCWidget').html(html); var callback = $('#paidSCWidget').attr('data-callback'); if(callback && window[callback]) { window[callback](); } customDimension.dimension72 += ' | Shown SYFT no Trial_With Missed Paywalled Articles Collection'; } else { _processNormal() } } }); } else { _processNormal(); } } catch (e) { _processNormal(); } }, function () { _processNormal(); }); //console.log('storyCollectionLoad', $); }

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with
in-depth insights that matter

• Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

  What Adani’s US indictment means for India Inc’s overseas fundraising

• Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

  Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?

• Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

  The problem with lab grown diamonds

• Why a falling rupee is a better option for the economy

  A list of top 20 momentum stocks that have delivered massive returns in one year

2Invest Wisely With Smart Market Tools & Investment Ideas

Alpha Trade

Get daily trade ideas from SEBI-registered research analysts.

Investment Ideas

Grow your wealth with stock ideas & sectoral trends.

Stock Reports Plus

All-in-one stock research with Stock Score, peer comparison & key signals.

BigBull Portfolio

Get to know where the market bulls are investing to identify the right stocks.

Stock Analyzer

Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.

Market Mood

Analyze the market sentiments & identify the trend reversal for strategic decisions.

Stock Talk Live at 9 AM Daily

Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.

3Stay informed anytime, anywhere with ET ePaper

ePaper - Print View

Read the PDF version of ET newspaper. Download & access it offline anytime.

ePaper - Digital View

Read your daily newspaper in Digital View & get it delivered to your inbox everyday.

Wealth Edition

Manage your money efficiently with this weekly money management guide.

TOI ePaper

Read the PDF version of TOI newspaper. Download & access it offline anytime.

Deep Explainers

Explore the In-depth explanation of complex topics for everyday life decisions.

Health+ Stories

Get fitter with daily health insights committed to your well-being.

Personal Finance+ Stories

Manage your wealth better with in-depth insights & updates on finance.

5Enjoy Complimentary Subscriptions From Top Brands

Stream new documentaries from all across the world every day.

Stories you might be interested in